Stelis Biopharma Begins Construction of Multiproduct Biologics Facility at Bioxcell Biotechnology Park, Malaysia
Stelis Biopharma has announced the groundbreaking for construction of its customized, multiproduct, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia’s premier park and ecosystem for industrial and healthcare biotechnology.
Stelis Biopharma (a wholly-owned subsidiary of Strides Arcolab) and Bio-XCell had previously announced the signing of a Build and Lease agreement with Bio-XCell for the construction of the building and part of the equipment of Stelis Biopharma’s 140,000 sq. foot biologics facility, for a total project investment amount of RM201 million (USD 60 million).
“Stelis is pleased to commence work on its flagship biopharmaceutical facility in Malaysia. With its strong commitment to bio-economy, attractive incentives, quality infrastructure and enabling ecosystem, we are confident of making this our bio-manufacturing hub for regional and global markets” said Joe Thomas, CEO of Stelis Biopharma, on the occasion.
The construction and fit-out of the facility is expected to be completed in 24 months and commercial operations are targeted to begin mid-2017 at Bio-XCell Park. The 140,000 sq ft facility will incorporate “next-gen” single-use bio-processing technology with both mammalian and microbial manufacturing suites. When complete, it will be one of the few regulated market approvable facilities in the region with end-to-end capability including sterile fill-finish across all formats. The facility will also house an R&D unit to conduct scale-up and process development studies.
“The partnership with Stelis Biopharma to build a multiproduct biologics facility from the start, is seen as a first in Bio-XCell biotechnology Park and timely given the close working relationship over the years. We are happy to see the second biopharma project to commence in Bio-XCell Park and for the facility to ground break over an aggressive construction timeline to see its operations in 2017.It is yet another positive step forward for the park to strengthen the value proposition of the Bio-XCell ecosystem as a regional hub for industrial biomanufacturing and bioprocessing” said Rizatuddin Ramli, CEO of BioXCell Malaysia.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance